COMMUNIQUÉS West-GlobeNewswire

AnaCardio´s Phase 1b/2a GOAL-HF1 study in patients with Heart Failure and Reduced Ejection Fraction (HFrEF) published in The Lancet
25/06/2026
Favourable safety profile in marked contrast to traditional inotropic therapeutics AC01 showed rapid and sustained numerical improvements in cardiac output, structure and function STOCKHOLM, Sweden, June 25, 2026 – [...]
Leads Biolabs Announces Partner Oblenio Bio’s $62 Million Oversubscribed Series B Financing to Advance Tri-Specific T-Cell Engager LBL‑051 for Autoimmune Diseases into Clinical Development
25/06/2026
NANJING, China, June 25, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its partner company with Aditum Bio, Oblenio Bio (“Oblenio [...]
BrewDog Inverurie Reopens with New Community Champions Model
25/06/2026
Opening set for Saturday 27 th June, featuring live music, entertainment and a sample pint on the house for the first 100 guests 1 New Community Champions model will support local initiatives, events, fundraising, [...]
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
25/06/2026
Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the evaluable 3 mg/kg and 6 mg/kg cohorts AX-0810 demonstrated up to 8-fold change [...]
Young workers willing to make career trade-offs for jobs with pensions: new research from HOOPP and Abacus Data
25/06/2026
TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- In an economy where young people feel increasing uncertainty about housing, saving money and the cost of living, nearly two-thirds of Canadians under the age of 35 say they [...]
EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis
25/06/2026
Hannover, Germany, June 25, 2026 (GLOBE NEWSWIRE) -- EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis [...]
Oblenio Bio Closes $62 Million Series B to Advance Tri-specific T-Cell Engager LBL-051 for Autoimmune Diseases into Clinical Development
25/06/2026
-- Round led by Pfizer Ventures, with participation from Deep Track Capital, GV, and founding investor, Aditum Bio -- --LBL-051’s ability to reset the immune system is supported by recent preclinical data presented at [...]
DeepHealth Receives Two FDA Clearances Enabling it to Add Cardiovascular Insights and Prior Exam Integration to its AI-Powered Breast Suite
25/06/2026
New capabilities are designed to improve cancer detection and recall rates and enable physicians to make informed cardiovascular decisions SOMERVILLE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a leader [...]
Herantis appoints experienced drug development expert Dr Juha Savola as Chief Medical Officer
25/06/2026
Brings more than 25 years of global drug development, regulatory and strategic leadership experience successfully guiding innovative therapies from clinical development through regulatory approval and commercialization [...]
AtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Markets
25/06/2026
AtaiBeckley to be added to the Russell 2000® Index and the broad-market Russell 3000® Index as part of 2026 reconstitution The Russell U.S. Indexes have approximately $12.2 trillion in assets benchmarked Inclusion [...]
Un nouveau projet de l’ACE pour soutenir les ergothérapeutes diplômés à l’étranger au Canada
25/06/2026
OTTAWA, Ontario, 25 juin 2026 (GLOBE NEWSWIRE) -- Un nouvel effort national est en cours afin de mieux soutenir les ergothérapeutes formés à l’étranger (EFE) dans l'avancement de leur carrière au Canada. L’Association [...]
Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
25/06/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small [...]
IBA to install the first proton therapy center in Brazil in Rio de Janeiro
25/06/2026
Louvain-La-Neuve, Belgium, June 25, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment [...]
IBA va installer le premier centre de protonthérapie du Brésil, à Rio de Janeiro
25/06/2026
Louvain-la-Neuve, Belgique, le 25 juin 2026 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le [...]
AnaCardio´s Phase 1b/2a GOAL-HF1 study in patients with Heart Failure and Reduced Ejection Fraction (HFrEF) published in The Lancet
25/06/2026
Favourable safety profile in marked contrast to traditional inotropic therapeutics AC01 showed rapid and sustained numerical improvements in cardiac output, structure and function STOCKHOLM, Sweden, June 25, 2026 – [...]
Press Release: Sanofi Foundation opens new chapter centered on future generations
25/06/2026
Sanofi Foundation opens new chapter centered on future generations Paris, June 2 5 , 2026 . The Sanofi Foundation is opening a new chapter with a strengthened commitment to children and young people, particularly those [...]
Communiqué de presse : La Fondation Sanofi ouvre un nouveau chapitre centré sur les générations futures
25/06/2026
La Fondation Sanofi ouvre un nouveau chapitre centré sur les générations futures Paris, 25 juin 2026 . La Fondation Sanofi ouvre un nouveau chapitre avec un engagement renforcé en faveur des enfants et des jeunes, en [...]
Herantis appoints experienced drug development expert Dr Juha Savola as Chief Medical Officer
25/06/2026
Brings more than 25 years of global drug development, regulatory and strategic leadership experience successfully guiding innovative therapies from clinical development through regulatory approval and commercialization [...]
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
25/06/2026
DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]

Pages